| Catalog No. | HB199016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | (VH-CH2-CH3)2 |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | sCD40L, Tumor necrosis factor ligand superfamily member 5, T-cell antigen Gp39, CD40L, TNFSF5, CD154, CD40-L, TNF-related activation protein, CD40 ligand, CD40LG, TRAP |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P29965 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -176°C. |
|---|
| Alternate Names | BMS-986004,CAS:1450981-87-9 |
|---|
| Background | Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
.jpg)
